Skip to content
Clinical Trials – home

Hospital Universitario Donostia

Verified siteinfo

Spain Pasealeku Doct. Begiristain 109, 20014 Donostia / San Sebastian, Spain

  • 62 trials recruiting
  • Breast cancer · Ovarian cancer · Endometrial cancer
  • Adults and children

About Specializations

Hospital Universitario Donostia in Donostia / San Sebastian, Spain specialises in clinical trials of conditions such as Breast cancer, Ovarian cancer, Endometrial cancer, Endometrial cancer recurrent, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases and Genetic Heart Disorders

At Hospital Universitario Donostia, research in cardiovascular disease focuses on protecting heart function and improving outcomes for people with inherited risk. The trials include studies in asymptomatic carriers of dilated cardiomyopathy-related variants, with the goal of preventing early heart damage and slowing disease progression.

  • Prevention of heart remodeling in genetic carriers at risk for dilated cardiomyopathy
  • Evaluation of treatments aimed at preserving left ventricular function
  • Research on early intervention for inherited cardiac disease

This area reflects a strong interest in early detection and preventive care within cardiology.

Breast Cancer and Other Solid Tumors

A major part of the clinical trial portfolio is dedicated to neoplasms, especially breast cancer. Studies are exploring new approaches for early-stage, advanced, and high-risk disease, including therapies designed to reduce recurrence, improve disease control, and support patients after standard treatment.

  • Testing new options for ER+/HER2- breast cancer and HER2-positive breast cancer
  • Evaluating treatments for advanced breast cancer and HER2-low disease
  • Long-term follow-up of patients treated for early breast cancer

The site also contributes to research in liver cancer, colon cancer, bladder cancer, and melanoma, broadening its oncology expertise.

Immunotherapy and Targeted Cancer Treatment

The research program includes trials assessing newer immunotherapy and targeted therapy strategies across several cancers. These studies aim to improve response rates, delay recurrence, and offer better options for patients whose disease has returned or no longer responds to standard treatment.

  • Testing immune-based treatments in advanced melanoma and liver cancer
  • Studying targeted approaches for advanced breast cancer
  • Exploring novel immune combinations in difficult-to-treat solid tumors

This work highlights the site’s role in advancing personalized cancer care through precision oncology.

Neurological Diseases and Movement Disorders

The site is also active in nervous system diseases, with studies addressing symptoms and long-term safety in conditions such as Parkinson’s disease, multiple sclerosis, and adrenomyeloneuropathy. These trials are designed to improve symptom control, monitor safety, and support better daily functioning.

  • Evaluating treatments for fatigue in Parkinson’s disease
  • Studying long-term safety in multiple sclerosis
  • Investigating therapy for adrenomyeloneuropathy

This portfolio shows a clear interest in chronic neurological conditions and patient-centered care.

Infectious Diseases and Inflammatory Conditions

Research in bacterial infections includes studies focused on serious infections that affect vulnerable patients, especially diabetic foot infections. The trials are intended to compare treatment effectiveness and safety, helping identify better options for infection control and recovery.

  • Comparing therapies for moderate to severe diabetic foot infections
  • Assessing safety and tolerability of new anti-infective treatment approaches
  • Supporting improved care for infection-related complications in diabetes

Alongside oncology and cardiology, this adds an important infectious disease dimension to the site’s research activity.

Urologic and Genitourinary Diseases

Clinical trials at Hospital Universitario Donostia also cover male urogenital and female urogenital diseases, including bladder cancer and pregnancy-related or other genitourinary conditions. The main aim is to evaluate new treatment combinations and improve outcomes for patients with complex disease.

  • Perioperative treatment research in muscle-invasive bladder cancer
  • Studies addressing broader genitourinary oncology needs
  • Exploration of improved treatment strategies for difficult-to-manage urogenital disease

These trials strengthen the site’s contribution to both oncology and urology.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Pasealeku Doct. Begiristain 10920014 Donostia / San SebastianSpain
Recruiting now
62 trials
Conditions studied
128
Partner status
Verified site

More sites in Donostia / San SebastianSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

159 clinical trials

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sargramostim
  • Sponsor:Greenwich LifeSciences Inc.

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:BeOne Medicines I GmbH

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

AUR200 for Patients with Generalized Myasthenia Gravis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AUR200

A study to evaluate the efficacy and safety of DYNE-101 in patients with Myotonic Dystrophy Type 1

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Humanised Igg1 Kappa Fragment Antibody Targeting Tfr1 Conjugated To P125 Oligonucleotide
  • Sponsor:Dyne Therapeutics Inc.

A study to evaluate the safety and effectiveness of surlorian in adults with RYR1-related myopathy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Rycarma Therapeutics Inc.

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:AZD5335
  • Sponsor:Astrazeneca AB

A study to evaluate the effectiveness and safety of ursodeoxycholic acid in patients with hepatorenal polycystic diseases.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ursodeoxycholic Acid
  • Sponsor:Asociacion Instituto Biogipuzkoa

A study to evaluate the effects of lutetium (177lu) vipivotide tetraxetan in patients with metastatic hormone sensitive prostate cancer receiving androgen deprivation therapy.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:University College London
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.